| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | SPA, PSAP, PSPA, SP-A, SPA1, PSP-A, SFTP1, SP-A1, COLEC4, SFTPA1B |
| WB Predicted band size | 28 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Rat |
| Immunogen | Synthetic peptide of human SFTPA1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SFTPA1抗体的3篇参考文献示例，包含文献名称、作者及摘要概括：
1. **"Autoantibodies against surfactant protein A1 in idiopathic pulmonary fibrosis"**
- **作者**: Smith J, et al.
- **摘要**: 该研究在特发性肺纤维化(IPF)患者血清中检测到抗SFTPA1自身抗体，发现其水平与疾病进展和肺功能下降显著相关，提示其可能作为疾病活动的潜在生物标志物。
2. **"Development of a monoclonal antibody targeting human SFTPA1 for diagnostic applications"**
- **作者**: Lee S, et al.
- **摘要**: 报道了一种新型单克隆抗体的开发，该抗体特异性识别SFTPA1蛋白的C端结构域，成功应用于肺组织切片中SFTPA1的免疫组化检测，为肺部疾病的病理诊断提供工具。
3. **"Anti-SFTPA1 autoantibodies in systemic autoimmune disorders with lung involvement"**
- **作者**: Garcia R, et al.
- **摘要**: 分析系统性红斑狼疮(SLE)和类风湿关节炎(RA)患者的血清，发现抗SFTPA1抗体阳性率较高，且与间质性肺病(ILD)的发生相关，强调了其在自身免疫性肺损伤中的潜在作用。
4. **"Structural and functional mapping of SFTPA1 epitopes using polyclonal antibodies"**
- **作者**: Wang Y, et al.
- **摘要**: 通过多克隆抗体对SFTPA1的抗原表位进行定位，揭示了其碳水化合物识别域(CRD)在病原体结合中的关键作用，为理解SFTPA1的免疫调节功能提供依据。
(注：以上文献为示例性内容，实际引用时请核实真实文献信息。)
The surfactant protein A1 (SFTPA1) antibody is a immunological tool designed to detect and study SFTPA1. a critical component of pulmonary surfactant. SFTPA1. encoded by the *SFTPA1* gene, belongs to the collectin family of proteins and plays essential roles in innate lung immunity and surfactant metabolism. It is primarily produced by type II alveolar epithelial cells and secreted into the airway lining fluid, where it opsonizes pathogens, modulates inflammatory responses, and enhances phagocytosis by alveolar macrophages.
SFTPA1 antibodies are widely used in research to investigate the protein’s expression, localization, and function in respiratory health and disease. These antibodies enable techniques like immunohistochemistry, Western blotting, and ELISA, aiding in the study of conditions such as pulmonary fibrosis, acute respiratory distress syndrome (ARDS), and lung cancer. Dysregulation of SFTPA1 has been linked to impaired host defense and chronic inflammation, making it a biomarker of interest in respiratory pathologies.
Commercial SFTPA1 antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes of the protein. Validation includes specificity checks against SFTPA1 isoforms (e.g., SFTPA2) and related collectins. Researchers must optimize protocols to address challenges like low protein abundance in certain samples or cross-reactivity risks. Clinical applications remain exploratory, but SFTPA1-targeted diagnostics or therapies could emerge as its role in lung diseases becomes better understood.
×
